{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:25:48Z","timestamp":1771565148226,"version":"3.50.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"14","license":[{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,6]]},"DOI":"10.1093\/eurheartj\/ehab717","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T14:19:03Z","timestamp":1632406743000},"page":"1428-1431","source":"Crossref","is-referenced-by-count":14,"title":["Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-275X","authenticated-orcid":false,"given":"Bertram","family":"Pitt","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Michigan School of Medicine , Ann Arbor, MI, USA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d'Investigations Cliniques Plurith\u00e9matique 1433 , Nancy, France"},{"name":"Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy, France"},{"name":"Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto , Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto , Porto, Portugal"}]}],"member":"286","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"key":"2022102517003990300_ehab717-B1","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1161\/CIRCRESAHA.118.313568","article-title":"Medical therapy for heart failure caused by ischemic heart disease","volume":"124","author":"Elgendy","year":"2019","journal-title":"Circ Res"},{"key":"2022102517003990300_ehab717-B2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"2022102517003990300_ehab717-B3","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"2022102517003990300_ehab717-B4","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"2022102517003990300_ehab717-B5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"2022102517003990300_ehab717-B6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102517003990300_ehab717-B7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102517003990300_ehab717-B8","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"for the PARADISE-MI Investigators and Committees. Angiotensin Receptor\u2013Neprilysin Inhibition in Acute Myocardial Infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102517003990300_ehab717-B9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure","volume":"46","author":"Pitt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2022102517003990300_ehab717-B10","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2022102517003990300_ehab717-B11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102517003990300_ehab717-B12","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/ejhf.900","article-title":"Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF","volume":"19","author":"Ferreira","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2022102517003990300_ehab717-B13","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1016\/j.ijcard.2013.06.091","article-title":"Mineralocorticoid receptor antagonist use in eligible patients following acute myocardial infarction: real world data from the Acute Coronary Syndrome Israeli Surveys: 2004-2010","volume":"168","author":"Koifman","year":"2013","journal-title":"Int J Cardiol"},{"key":"2022102517003990300_ehab717-B14","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/ejhf.2191","article-title":"Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics","volume":"23","author":"Jering","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102517003990300_ehab717-B15","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jacc.2015.12.042","article-title":"Predicting persistent left ventricular dysfunction following myocardial infarction: the PREDICTS study","volume":"67","author":"Brooks","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022102517003990300_ehab717-B16","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/14\/1428\/46629579\/ehab717.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/14\/1428\/46629579\/ehab717.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T18:16:27Z","timestamp":1666721787000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/14\/1428\/6425576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"references-count":16,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2021,11,12]]},"published-print":{"date-parts":[[2022,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab717","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,7]]},"published":{"date-parts":[[2021,11,12]]}}}